However, when Tnfsf9 expression at the tumor was combined with rIL-12, survival outcomes were similar across genotypes: 69.2% of Il12b+/+ mice (Figures 6H and S7B) and 63.6% of Il12b−/− mice (Figure S7E) survived beyond 50 days, indicating that exogenous rIL-12 can compensate for the absence of endogenous IL-12. This evidence concerns the gene TNFSF9 and neoplasm.